cronos group glp-1 receptor agonists weight management diabetes treatments agonism: a transformative approach for managing type-2 and obesity | Saudi Pharmaceutical Journal Advances in GLP-1 receptor agonists

Discussion GLP-1R agonists are promising agents for treating type 2 diabetes mellitus that reduce blood glucose via glucose-dependent insulin secretion with minimized low risk of hypoglycaemia

The drugs manufacturer, Eli Lilly, is expected to seek FDA approval soon, which could make the medication available within the next several months

Drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have shown to improve efficacy compared to older weight-loss medications, with patients losing up to 20% of their body weight

Suicidal ideation is associated with the use of various weight reduction drugs [67,68]

185 Another incretin hormone was then discovered, GLP-1, which was first identified in the translational products of mRNAs isolated from anglerfish pancreatic islets

In comparison, oral semaglutide only reduced HbA1c by 1.47%